Sarepta Therapeutics, Inc. (SRPT)
22.20
+0.03
(+0.14%)
USD |
NASDAQ |
Dec 10, 16:00
22.06
-0.14
(-0.63%)
After-Hours: 20:00
Sarepta Therapeutics Research and Development Expense (Quarterly): 218.89M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Pfizer Inc. | 2.492B |
| Arrowhead Pharmaceuticals, Inc. | 168.80M |
| Amgen, Inc. | 1.90B |
| Bristol Myers Squibb Co. | 2.433B |
| Alnylam Pharmaceuticals, Inc. | 358.81M |